The 2,000 patient-study will use Fluidigm’s Mass Cytometry technology.
- Could Bioelectronic Medicine Play a Role in Treating COVID-19 Symptoms?
- Exit TransEnterix: Enter Asensus Surgical
- FDA Pivots on COVID-19 Guidance for Product Developers
- Millions of Americans Can Benefit from Your Medtech Innovations
- Can Next-Gen Sensors Transform Surgical Robotics and Other Precision Medical Devices?
- FDA Lays Out Flaws Made in Initial Antibody Testing Guidance